Achievements of rheumatology in the XXI century: contribution of Russian rheumatology
https://doi.org/10.30629/0023-2149-2023-102-3-197-204
Abstract
Rheumatology is one of the most rapidly developing medical specialties, which effectively adapts achievements and contributes to the progress of the world fundamental and clinical medical science [1]. Such immuno-inflammatory rheumatic diseases (IVRS) both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are not only the most severe chronic inflammatory human diseases, but also “models” for studying the fundamental mechanisms of pathogenesis and approaches to pharmacotherapy of other diseases associated with the development of autoimmunity and/or auto-inflammation. The relevance of the problem of IVR for modern medicine is determined by their high prevalence in the population, the difficulty of early diagnosis, the rapid development of disability and an unfavorable life prognosis. Deciphering the mechanisms of immunopathogenesis, improving diagnostics, molecular taxonomy, developing approaches to prevention, searching for new “targets” of IVR therapy based on “omix” technologies and artificial intelligence are among the priority areas of biology and medicine of the XXI century.
About the Authors
I. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology;
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia (Sechenov University)
Russian Federation
Russian Federation
Evgeny L. Nasonov — Dr of Sci. (Med.), Professor, Academician of the RASS, scientific director of the Federal State Budgetary Institution Research Institute named after V.A. Nasonova, head of the Department of Rheumatology of the First Moscow State Medical University named after I.M. Sechenov
Moscow
A. М. Lila
V.A. Nasonova Research Institute of Rheumatology;
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russia
Russian Federation
Russian Federation
Alexander M. Lila — Dr. of Sci. (Med.), Professor, Corresponding Member RAS, Director of the Federal State Budgetary Institution Research Institute named after V. A. Nasonova, Head of the Department of Rheumatology of the Federal State Budgetary Educational Institution of Further Professional Education RMANPO
Moscow
References
1. Nasonov E.L. Achievements in rheumatology in the XXI century. Rheumatology Science and Practice. 2014;52(2):133–140. (In Russian). DOI: 10.14412/1995-4484-2014-133-140
2. Popkova T.V., Novikova D.S., Nasonov E.L. Cardiovascular diseases in rheumatoid arthritis: latest data. Rheumatology Science and Practice. 2016;54(2): 122–128. (In Russian). DOI: 10.14412/1995-4484-2016-122-128
3. Nasonov E.L., Ananyeva L.P., Avdeev S.N. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Rheumatology Science and Practice. 2022;60(6):517– 534. (In Russian). DOI: 10.47360/1995-4484-2022-1
4. Kondratyeva L.V., Popkova T.V., Nasonov E.L. Metabolic syndrome in rheumatoid arthritis. Rheumatology Science and Practice. 2013;51(3):302–312. (In Russian). DOI: 10.14412/1995-4484-2013-1506
5. Nasonov E.L. Modern concept of autoimmunity in rheumatology. Rheumatology Science and Practice. 2023;61(4):397– 420. (In Russian). DOI: 10.47360/1995-4484-2023-397-420
6. Nasonov E.L., Aleksandrova E.N., Novikov A.A. Autoimmune rheumatic diseases: results and prospects for researches. Rheumatology Science and Practice. 2015;53(3):230– 237. (In Russian). DOI: 10.14412/1995-4484-2015-230-237
7. Beketova T.V. The development of rheumatology at the stage of formation of a new technological paradigm. Rheumatology Science and Practice. 2019;57(5):490– 495. (In Russian). DOI: 10.14412/1995-4484-2019-490-495
8. Aleksandrova E.N., Nasonov E.L. Innovative technologies in the laboratory diag nosis of rheumatic diseases. Rheumatology Science and Practice. 2010;48(2):13–20. (In Russian). DOI: 10.14412/1995-4484-2010-1411
9. Aleksandrova E.N., Novikov A.A., Nasonov E.L. Current approaches to the laboratory diagnosis of rheumatic diseases: role of molecular and cellular biomarkers. Rheumatology Science and Practice. 2016;54(3):324– 338. (In Russian). DOI: 10.14412/1995-4484-2016-324-338
10. Nasonov E.L. Pharmacotherapy for rheumatoid arthritis: new strategy, new targets. Rheumatology Science and Practice. 2017;55(4):409–419. (In Russian). DOI: 10.14412/1995-4484-2017-409-419
11. Nasonov E.L. New possibilities of pharmacotherapy for immunoinfl ammatory rheumatic diseases: a focus on inhibitors of interleukin-17. Rheumatology Science and Practice. 2017;55(1):68–86. DOI: 10.14412/1995-4484-2017-68-86
12. Nasonov E.L., Lila A.M. Inhibition of inter leukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Rheumatology Science and Practice. 2017;55(6):590–599. (In Russian). DOI: 10.14412/1995-4484-2017-590-599
13. Nasonov E.L. The role of interleukin 1 in the development of human diseases. Rheumatology Science and Practice. 2018;56:19–27. (In Russian). DOI: 10.14412/1995-4484-2018-19-27
14. Nasonov E.L., Korotaeva T.V., Rodolfi S., Selmi C.F. Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data. Rheumatology Science and Practice. 2022; 60(1):80–90. (In Russian). DOI: 10.47360/1995-4484-2022-80-90
15. Beketova T.V., Arseniev E.V. Interleukin-5 is a new target in the treatment of eosinophilic granulomatosis with polyangiitis. Rheumatology Science and Practice. 2020;58(3):321–329. (In Russian). DOI: 10.14412/1995-4484-2020-321-329
16. Karateev A.E., Lila A.M., Alekseeva L.I. Use of tanezumab for chronic pain treatment. Rheumatology Science and Practice. 2021;59(2):192–200. (In Russian). DOI: 10.47360/1995-4484-2021-192-200
17. Nasonov E.L., Beketova T.V., Ananyeva L.P., Vasilyev V.I., Solovyev S.K., Avdeeva A.S. Prospects for anti-b-cell therapy in immuno-inflammatory rheumatic diseases. Rheumatology Science and Practice. 2019;57:1–40. (In Russian). DOI: 10.14412/1995-4484-2019-3-40
18. Nasonov E.L. Abatacept for rheumatoid arthritis: a novel formulation, new mechanisms, new possibilities. Rheumatology Science and Practice. 2015;53(5):522– 541. (In Russian). DOI: 10.14412/1995-4484-2015-522-541
19. Nasonov E.L., Popkova T.V., Lila A.M. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Rheumatology Science and Practice. 2021;59(4):367–383. (In Russian). DOI: 10.47360/1995-4484-2021-367-383
20. Nasonov E.L., Avdeeva A.S., Popkova T.V. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Rheumatology Science and Practice. 2021;59(5):537–546. (In Russian). DOI: 10.47360/1995-4484-2021-537-546
21. Nasonov E.L., Lila A.M. Janus kinase inhibitors in immuno-infl ammatory rheumatic diseases: new opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8–16. (In Russian). DOI: 10.14412/1995-4484-2019-8-16
22. Nasonov E.L., Mazurov V.I., Karateev D.E., Lukina G.V., Zhilyaev E.V. et al. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian public organization “Association of Rheumatologists of Russia” — 2014 (PART 1). Rheumatology Science and Practice. 2014;52(5):477–494. (In Russian). DOI: 10.14412/1995-4484-2014-477-494
23. Nasonov E.L., Amirdjanova V.N., Olyunin Y.A., Muravyev Y.V., Baranov A.A., Zonova E.V., Otteva E.N., Zagrebneva A.I., Abdulganieva D.I., Pchel nikova P.I. The use of methotrexate in rheumatoid arthritis. Recommen dations of the All-Russian public organization “Association of Rheuma tologists of Russia”. Rheumatology Science and Practice. 2023; 61(4):435–449. (In Russian). DOI: 10.47360/1995-4484-2023-435-449
24. Dubinina T.V., Gaidukova I.Z., Godzenko A.A., Lapshina S.A., Rebrov A.P. et al. Guidelines for the assessment of disease activity and functional status in patients with ankylosing spondylitis in clinical practice. Rheumatology Science and Practice. 2017;55(4):344–350. (In Russian). DOI: 10.14412/1995-4484-2017-344-350
25. Korotaeva T.V. Psoriatic arthritis: classification, clinical presentation, diagnosis, treatment. Rheumatology Science and Practice. 2014;52(6):650–659. (In Russian). DOI: 10.14412/1995-4484-2014-650-659
26. Eliseev M.S. ACR management guidelines for the treatment of gout: What’s new and what’s controversial. Rheumatology Science and Practice. 2021;59(2):129–133. (In Russian). DOI: 10.47360/1995-4484-2021-129-133
27. Panafidina T.A., Popkova T.V., Solovyev S.K. Monitoring patients with systemic lupus erythematosus: general characteristics and discussion questions (according to the Canadian Rheumatology Association recommendations). Rheumatology Science and Practice. 2019;57(3):255–264. (In Russian). DOI: 10.14412/1995-4484-2019-255-264
28. Beketova T.V., Popov I.Yu., Babak V.V. Review of guideline for the management of ANCAassociated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation. Rheumatology Science and Practice. 2021;59(6):684–692. (In Russian). DOI: 10.47360/1995-4484-2021-684-692
29. Belov B.S., Kuzmina N.N., Medyntseva L.G., Babaeva A.R., Shostak N.A. et al. Diagnosis of acute rheumatic fever. Rheumatology Science and Practice. 2016;54(4):395–397. (In Russian). DOI: 10.14412/1995-4484-2016-395-397
30. Belov B.S., Ananyeva L.P. Lyme disease: Modern approaches to prevention, diagnosis and treatment. Rheumatology Science and Practice. 2021;59(5):547– 554. (In Russian). DOI: 10.47360/1995-4484-2021-547-554
31. Lisitsyna T.A., Alekberova Z.S., Goloeva R.G. New guidelines for the management of patients with Behcet’s disease/syndrome (EULAR, 2018). Rheumatology Science and Practice. 2019;57(2):133–141. (In Russian). DOI: 10.14412/1995-4484-2019-133-141
32. Sokol E.V. The new 2019 American college of rheumatology (ACR)/ European League Against Rheumatism (EULAR) classification criteria for IgG4-related disease. Rheumatology Science and Practice. 2020;58(4):368–375. (In Russian). DOI: 10.47360/1995-4484-2020-368-375
33. Toroptsova N.V. Review of American college of rheumatology (acr) clinical guidelines for the prevention and treatment of glucocorticoid–induced osteoporosis. Rheumatology Science and Practice. 2018;56(2):144–151. (In Russian). DOI: 10.14412/1995-4484-2018-144-151
34. Safonova Yu.A., Zotkin E.G., Toroptsova N.V. Diagnosis for risk for falls and their prevention: draft clinical guidelines by the Association of Rheumatologists of Russia and the Russian Osteoporosis Association. Rheumatology Science and Practice. 2020;58(2):133–139. (In Russian). DOI: 10.14412/1995-4484-2020-133-139
35. Belov B.S., Tarasova G.M., Muravyevа N.V. Vaccination in rheumatology (the 2019 update of EULAR recommendations). Rheumatology Science and Practice. 2019;57(6):618–625. (In Russian). DOI: 10.14412/1995-4484-2019-618-625
36. Amirjanova V.N., Makarov M.A., Karateev A.E., Khramov A.E., Maglevaniy S.V., Rozov A.V., Nesterenko V.A., Nasonov E.L. Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022. Rheumatology Science and Practice. 2023;61(3):260–267. (In Russian). DOI: 10.47360/1995-4484-2023-260-267
37. Nasonov E.L., Lila A.M., Mazurov V.I., Belov B.S., Karateev A.E. et al. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Rheumatology Science and Practice. 2021;59(3):239–254. (In Russian). DOI: 10.47360/1995-4484-2021-239-254
38. Popkova T.V., Novikova D.S. According to the materials of the 2015/2016 new European league against rheumatism (eular) guidelines for reducing cardiovascular risk in patients with inflammatory arthritis: general characterization and discussion problems. Rheumatology Science and Practice. 2018;56(3):272– 279. (In Russian). DOI: 10.14412/1995-4484-2018-272-279
39. Karateev A.E., Nasonov E.L., Ivashkin V.T., Martynov A.I., Yakhno N.N. et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1–29. (In Russian). DOI: 10.14412/1995-4484-2018-1-29
40. Nasonov E.L., Yakhno N.N., Karateev A.E., Alekseeva L.I., Barinov A.N. et al. General principles of treatment for musculoskeletal pain: interdisciplinary consensus. Rheumatology Science and Practice. 2016;54(3):247–265. (In Russian). DOI: 10.14412/1995-4484-2016-247-265
41. Nasonov E.L. Biosimilars in rheumatology. Rheumatology Science and Practice. 2016;54(6):628– 640. (In Russian). DOI: 10.14412/1995-4484-2016-628-640
42. Nasonov E.L. Pharmacotherapy for rheumatoid arthritis: russian and international guidelines. Rheumatology Science and Practice. 2016;54(5):557– 571. (In Russian). DOI: 10.14412/1995-4484-2016-557-571
43. Nasonov E.L. Problems of rheumatoid arthritis immunopathology: evolution of the disease. Rheumatology Science and Practice. 2017;55(3):277–294. (In Russian). DOI: 10.14412/1995-4484-2017-277-294
44. Nasonov E.L., Avdeeva A.S., Dibrov D.A. Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease. Rheumatology Science and Practice. 2023;61(3):276–291. (In Russian). DOI: 10.47360/1995-4484-2023-276-291
45. Nasonov E.L., Olyunin Yu.A., Lila A.M. Rheumatoid arthritis: the problems of remission and therapy resistance. Rheumatology Science and Practice. 2018;56(3):263–271. (In Russian). DOI: 10.14412/1995-4484-2018-263-271
46. Filatova E.S., Karateev A.E., Lila A.M., Nasonov E.L. Functional magnetic resonance imaging for chronic pain in patients with rheumatic diseases. Rheumatology Science and Practice. 2019;57(6):612–617. (In Russian). DOI: 10.14412/1995-4484-2019-612-617
47. Korshunov N.I., Kurygin A.G., Rechkina E.V., Filatova Yu.S., Yaltseva N.V. Rheumatoid arthritis as a psychosomatic disease. Rheumatology Science and Practice. 2015;53(5):469–471. (In Russian). DOI: 10.14412/1995-4484-2015-469-471
48. Karateev A.E., Karateev D.E., Davydov O.S. Pain and inflammation. Part 1. Pathogenetic aspects. Rheumatology Science and Practice. 2016;54(6):693–704. DOI: 10.14412/1995-4484-2016-693-704
49. Karateev A.E., Nasonov E.L. Chronic pain and central sensitization in immuno-inflammatory rheumatic diseases: pathogenesis, clinical manifestations, the possibility of using targeted disease modifying antirheumatic drugs. Rheumatology Science and Practice. 2019;57(2):197–209. (In Russian). DOI: 10.14412/1995-4484-2019-197-209
50. Lisitsyna T.A., Veltishchev D.Yu., Seravina O.F., Kovalevskaya O.B. et al. Proinflammatory cytokines and depression in rheumatoid arthritis. Rheumatology Science and Practice. 2013;51(3):261–266. (In Russian). DOI: 10.14412/1995-4484-2013-1498
51. Solovyev S.K., Aseeva E.A., Popkova T.V., Lila A.M., Mazurov V.I., Nasonov E.L. Systemic lupus erythematosus: new horizons for diagnosis and therapy. Rheumatology Science and Practice. 2020;58(1):5–14. (In Russian). DOI: 10.14412/1995-4484-2020-5-14
52. Mesnyankina A.A. Cellular and molecular biomarkers and potential therapeutic targets in systemic lupus erythematosus. Rheumatology Science and Practice. 2016;54(2):206–218. (In Russian). DOI: 10.14412/1995-4484-2016-206-218
53. Aseeva E.A., Soloviev S.K., Mesnyankina A.A., Reshetnyak T.M., Lopatina N.E., Glukhova S.I., Nasonov E.L. Results of an observational prospective study of the efficacy and safety of belimumab (Benlysta®) in systemic lupus erythematosus in real clinical practice. Rheumatology Science and Practice. 2016;54(1):31–37. (In Russian). DOI: 10.14412/1995-4484-2016-31-37
54. Aseeva E.A., Soloviev S.K., Mesnyankina A.A., Tsanyan M.E., Nasonov E.L. Experience with belimumab in patients with systemic lupus erythematosus. Rheumatology Science and Practice. 2015;53(3):329–335. (In Russian). DOI: 10.14412/1995-4484-2015-329-335
55. Mesnyankina A.A., Solovyev S.K., Aleksandrova E.N., Aleksankin A.P., Aseeva E.A., Nasonov E.L. Dual therapy with biologicals in patients with systemic lupus erythematosus. Rheumatology Science and Practice. 2016;54(3):281–288. (In Russian). DOI: 10.14412/1995-4484-2016-281-288
56. Mesnyankina A.A., Solovyev S.K., Aseeva E.A., Nasonov E.L. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Rheumatology Science and Practice. 2018;56(3): 302–309. (In Russian). DOI: 10.14412/1995-4484-2018-302-309
57. Nasonov E.L., Avdeeva A.S. Immunoinflammatory rheumatic diseases associated with type i interferon: new evidence. Rheumatology Science and Practice. 2019;57(4):452–461. (In Russian). DOI: 10.14412/1995-4484-2019-452-461
58. Nasonov E.L., Mazurov V.I., Zonova E.V., Knyazeva L.A., Marusenko I.M. et al. The efficacy and safety of rituximab biosimilar (Acellbia®) in rheumatoid arthritis as the first biological agent: results of phase III (ALTERRA) clinical trial. Rheumatology Science and Practice. 2017;55(4):351–359. (In Russian). DOI: 10.14412/1995-4484-2017-351-359
59. Nasonov E.L., Zonova E.V., Ivanova O.N., Knyazeva L.A., Mazurov V.I. et al. The results of a phase III comparative clinical trial of rituximab (Acellbia® and Mabthera®) in rheumatoid arthritis (the BIORA study). Rheumatology Science and Practice. 2016;54(5):510– 519. (In Russian). DOI: 10.14412/1995-4484-2016-510-519
60. Korolev M.A., Ubshaeva Yu.B., Banshchikova N.Y., Letyagina E.A., Mullagaliev A.A. The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study). Rheumatology Science and Practice. 2020;58(6):663–672. (In Russian). DOI: 10.47360/1995-4484-2020-663-672
61. Avdeeva A.S., Artyukhov A.S., Dashinimaeva E.B., Cherkasova M.V., Nasonov E.L. Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). Rheumatology Science and Practice. 2019;57(1):46–55. (In Russian). DOI: 10.14412/1995-4484-2019-46-55
62. Avdeeva A.S., Cherkasova M.V., Kusevich D.A., Rybakova V.V., Nasonov E.L. Immunological effects of a rituximab biosimilar (acelbia, biocad) in patients with rheumatoid arthritis. Rheumatology Science and Practice. 2018;56(5):556–563. (In Russian). DOI: 10.14412/1995-4484-2018-556-563
63. Korotaeva T.V., Mazurov V.I., Lila A.M., Gaydukova I.Z., Bakulev A.L., Samtsov A.V. et al. Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. Rheumatology Science and Practice. 2020;58(5):480–488. (In Russian). DOI: 10.47360/1995-4484-2020-480-488
64. Mazurov V.I., Gaydukova I.Z., Erdes S., Dubinina T.V., Pristrom A.M. et al. Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized doubleblind clinical trial BCD-085-5/ASTERA. Rheumatology Science and Practice. 2020;58(4):376–386. (In Russian). DOI: 10.47360/1995-4484-2020-376-386
65. Lila A.M., Mazurov V.I., Zonova E.V., Nesmeyanova O.B., Plaksina T.V. et al. Comparative evaluation of the long-term efficacy and safety of the infliximab biosimilar BCD055 and reference infliximab in patients with ankylosing spondylitis: results of the international multicenter randomized double-blind phase III clinical study ASART-2. Rheumatology Science and Practice. 2018;56(3):293–301. (In Russian). DOI: 10.14412/1995-4484-2018-293-301
66. Feist E., Nasonov E. Interleukin 6 Inhibition in Rheumatoid Arthritis: Highlight on Olokizumab. touchREVIEWS in RMD. 2023;2(1):17– 27. DOI: 10.17925/RMD.2023.2.1.17
67. Feist E., Fatenejad S., Grishin S., Korneva E., Luggen M.E., Naso nov E. et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann. Rheum. Dis. 2022;81(12):1661– 1668. DOI: 10.1136/ard-2022-222630
68. Nasonov E., Fatenejad S., Feist E., Ivanova M., Korneva E. et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann. Rheum. Dis. 2022;81(4):469–479. DOI: 10.1136/annrheumdis-2021-219876
69. Smolen J.S., Feist E., Fatenejad S., Grishin S.A., Korneva E.V., Nasonov E.L., Samsonov M.Y., Fleischmann R.M. CREDO2 Group. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N. Engl. J. Med. 2022;387(8):715–726. DOI: 10.1056/NEJMoa2201302
70. Korotaeva T.V., Zotkin E.G., Nesmeyanova O.B., Vezikova N.N., Ershova O.B. et al. Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2. Rheumatology Science and Practice. 2017;55(2):151–158. (In Russian). DOI: 10.14412/1995-4484-2017-151-158
71. Erdes S.F., Denisov L.N., Maslyansky A.L., Ershova O.B., Stanislav M.L., Salnikova T.S., Izmozherova N.V., Lesnyak O.M. Anti-interleukin-17 monoclonal antibody for the treatment of ankylosing spondylitis: results of analysis of a russian patient group from the randomized, double-blind, placebocontrolled MEASURE 1 and MEASURE 2 trials. Rheumatology Science and Practice. 2017;55(1):17–25. (In Russian). DOI: 10.14412/1995-4484-2017-17-25
72. Nasonov E.L., Stanislav M.L., Raskina T.A., Kuropatkin G.V., Shirinsky I.V. et al. Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study). Rheumatology Science and Practice. 2019;57(2):142–148. (In Russian). DOI: 10.14412/1995-4484-2019-142-148
73. Nasonov E.L. Coronavirus disease 2019 (COVID-19): a rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123–132. DOI: 10.14412/1995-4484-2020-123-132
74. Nasonov E.L., Beketova T.V., Reshetnyak T.M., Lila A.M., Ananieva L.P., Lisitsyna T.A., Soloviev S.K. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Rheumatology Science and Practice. 2020;58(4):353– 367. (In Russian). DOI: 10.47360/1995-4484-2020-353-367
75. Nasonov E.L. Coronavirus disease 2019 (COVID-19) and autoimmunity. Rheumatology Science and Practice. 2021;59(1):5– 30. (In Russian). DOI: 10.47360/1995-4484-2021-5-30
76. Nasonov E.L., Samsonov M.Y. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed. Pharmacother. 2020;131:110698. DOI: 10.1016/j.biopha.2020.110698
77. Nasonov E.L., Samsonov M.Y., Lila A.M. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her. Russ. Acad. Sci. 2022;92(4):398–403. DOI: 10.1134/S1019331622040062
Review
For citations:
Nasonov I.L., Lila A.М. Achievements of rheumatology in the XXI century: contribution of Russian rheumatology. Clinical Medicine (Russian Journal). 2024;102(3):197-204. (In Russ.) https://doi.org/10.30629/0023-2149-2023-102-3-197-204
Views:
425
Email this article 